| Description: |
The iPSC facility at the CHG was established under the Transgenic core to provide essential genome engineering services to research groups in in the building and around Oxford. In 2022 the iPSC facility became an independent research group specializing in genome engineering of human iPSCs and stem cell differentiations.
The facility have optimized protocols for generation of cortical neurons, monocytes/microglia, cerebral organoids, cortical organoids, endothelial cells, smooth muscle cells, cardiac myocytes, cardiac fibroblasts, vascular organoids and kidney organoids. They offer service projects in the above-mentioned technologies to both academic laboratories and industry partners.
|
